Enzalutamide monotherapy? Plus, nivolumab & pembrolizumab approval updates
Oct 19, 2023•17 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
This week we discuss the continued push to introduce 2nd generation androgen inhibitors earlier into treatment with the EMBARK trial.
Nivolumab and pembrolizumab, pemrolizumab and nivolumab. Again and again. Their role (and approvals) for adjuvant melanoma make sense. But what to think about their use for NSCLC in the neoadjuvant setting?
West commentary: https://dailynews.ascopubs.org/do/should-induction-chemoimmunotherapy-lead-us-broaden-our-definition-resectability-nsclc
For the best experience, listen in Metacast app for iOS or Android